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Abstract 
Objectives: In order to determine how gene expression is altered in disease it is of fundamental importance that 
the global distribution of gene expression levels across the disease‑free brain are understood and how differences 
between tissue types might inform tissue choice for investigation of altered expression in disease state. The aim of 
this pilot project was to use RNA‑sequencing to investigate gene expression differences between five general areas 
of post‑mortem human brain (frontal, temporal, occipital, parietal and cerebellum), and in particular changes in gene 
expression in the cerebellum compared to cortex regions for genes relevant to Alzheimer’s disease, as the cerebellum 
is largely preserved from disease pathology and could be an area of interest for neuroprotective pathways.
Results: General gene expression profiles were found to be similar between cortical regions of the brain, however 
the cerebellum presented a distinct expression profile. Focused exploration of gene expression for genes associated 
with Alzheimer’s disease suggest that those involved in the immunity pathway show little expression in the brain. 
Furthermore some Alzheimer’s disease associated genes display significantly different expression in the cerebellum 
compared with other brain regions, which might indicate potential neuroprotective measures.
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Introduction
RNA-sequencing is now at the forefront of genetic 
research into complex disease, for accurate quantita-
tion of gene expression and has been found to provide 
more comprehensive view of the RNA landscape than 
microarrays [1]. Whereas most expression studies have 
focused on differential gene expression between control 
and disease tissue, few investigate differential expres-
sion observed between different tissues from the same 
individual. In order to determine how gene expression 
is altered in disease or pre-disease state it is of funda-
mental importance that the global distribution of gene 
expression levels is understood and how this might dif-
fer between tissue types to inform accurate tissue choice 
for investigation of altered expression in disease state. 
Online databases such as the Genotype-Tissue Expres-
sion (GTEx) project [2] are extremely helpful in deter-
mining this, however there is a need to gain insight for 
gene expression profiles in tissues from the same sam-
ples, as individual differences between samples (e.g. 
genetic background) might mask true positive findings 
and extenuate false positive finding.
The Brains for Dementia Research (BDR) cohort is an 
initiative to provide tissue for investigation into the aeti-
ology of dementia. The cohort consists of well-defined 
clinically and neuropathological post-mortem brain tis-
sue from healthy control and dementia samples, with the 
majority diagnosed as Alzheimer’s disease (AD). Recent 
RNA-sequencing studies comparing AD and control 
tissue compare either a single region, or a few specific 
regions or cell-types of the brain, producing variable 
results for the genes displaying significant difference in 
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expression between disease states [3–6]. This may be due 
to some genes showing expression differences between 
disease states in some regions but not others. Therefore 
in order to establish how reflective such studies are of 
each other, the gene expression profile across different 
brain regions must be conducted in corresponding tissue 
from the same subject. The discernment of which genes 
are differentially expressed between brain regions and 
not others could aid our understanding as to why certain 
regions of the brain are susceptible to various neurode-
generative diseases and help inform which region should 
be studied in relation to certain genes or pathways.
Main text
Methods
Three neuro-pathologically confirmed healthy controls 
were selected from the BDR repository. With three bio-
logical replicates per brain region, there is 87% power 
to detect gene expression fold-changes > 2 [7]. Tissue 
samples from five regions of the brain (frontal, tempo-
ral, occipital, parietal and cerebellum) were provided 
for each of the three samples. Two of the samples were 
female, with one male sample, the average age of death 
was 71 years (± 14 years), and average PMI = 50.3 h.
RNA was isolated from each of the regions using an in-
house developed methodology preparing tissue with the 
Covaris cryoPrep system, to crush the tissue to increase 
the surface area and allowing efficient cell lysis in 1  ml 
TriZol following by RNA extraction with the RNAeasy 
Minikit from QIAGEN. A total of 2 μg of RNA was sent 
to the University of Nottingham DeepSeq Facility, for 
library preparation and sequencing. Total RNA samples 
were processed for ribosomal RNA depletion in order to 
enrich for non-coding and coding genes. Enriched RNA 
samples were then used to generate barcoded-sequencing 
libraries. Libraries were multiplexed onto 20 high output 
runs (2 × 75 bp) generating around 60 million reads per 
sample with sequencing performed using Illumina Next-
seq500 platform.
The filtering pipeline was used to filter reads with low 
sequencing score as well as reads aligned to adaptor 
sequences. First, raw reads were trimmed against adap-
tors using ‘Sythe’ (https ://githu b.com/vsbuff alo/scyth 
e), then reads were quality trimmed using ‘Sickle’ (https 
://githu b.com/najos hi/sickl e). Reads passing the filters 
were mapped onto the reference genome (hg19) in the 
context of known gene exon coordinates (Ensembl) using 
the ‘tophat’ mapping tool. (https ://ccb.jhu.edu/softw are/
topha t/index .shtml ).
Read counts for each gene were calculated using ‘htseq-
count’ (http://www-huber .embl.de/users /ander s/HTSeq /
doc/count .html). RPKM (reads per kilobase of transcript 
per million mapped reads) counts for all genes were 
calculated [8]. The RPKM is simply a normalized read 
count (stranded/sense reads) for a given gene. The read 
count of the exon-space of a gene is normalised against 
the total number of mapped reads against the total length 
of the gene’s exon-space. Genes with an average RPKM 
of < 1 were deemed non-discriminatory from background 
noise [9] and should be viewed with caution.
Statistical analysis
The programme ‘DESeq2’ [10] was used to detect dif-
ferentially expressed genes between brain regions in a 
pair-wise fashion. This analysis uses the gene counts, 
and corrects for dispersion using Bayes theorem. The 
final values for differential expression are adjusted with a 
Benjamini-Hochberg (false discovery rate—FDR) with a 
P value < 0.05 deemed as significant.
Results
There was an average of 15,742 genes expressed across 
the 15 samples with an RPKM greater than 1, indicating 
gene expression above background noise [9]. Each region 
displayed a varying number of genes expressed, with the 
cerebellum expressing the greatest number of genes with 
an average of 16,576 across the three samples. The fron-
tal, temporal, occipital and parietal cortex regions dis-
played expression of 15,450; 14,930; 15,995 and 15,757 
genes, respectively. One-way ANOVA with post hoc 
Tukey revealed a significant difference between the num-
ber of genes expressed between the temporal and cer-
ebellum regions (P = 0.023). No other comparisons were 
significant (P > 0.1). Across all regions the most highly 
expressed genes were SRP and RNU RNA genes, involved 
in translation and splicing mechanisms.
There was an average of 20,132 gene comparisons 
analysed per region (based on gene count), suggesting 
that around 1000 (5%) genes would be found to be dif-
ferentially expression by chance at the alpha significance 
threshold (P < 0.05 FDR corrected). In differential analy-
ses between cortex regions far fewer genes were identi-
fied than this. Comparisons between the cerebellum and 
each cortex region suggested that 6–9 times more than 
the expected number of genes by chance were observed 
to be significantly differentially expressed (Table 1).
Gene expression in the cerebellum region was vastly 
different, with 11,770 unique genes differentially 
expressed compared to the other regions. Five thousand, 
three hundred and one genes (45%) were consistently 
differentially expressed between the cerebellum and the 
other cortex regions. The majority of these were concord-
ant for direction of expression level change in the cere-
bellum compared to the other regions, with only 14 genes 
(0.3%) showing divergent expression direction changes 
between the cerebellum and each of the cortex regions.
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Preliminary exploration of the data with Ingenuity’s 
Pathway Analysis (IPA) software (QIAGEN Bioinfor-
matics) suggests that the common gene expression 
differences in the cerebellum indicate decreases in the 
development and quantity of neurons, and an increase 
in neuronal loss in the cerebellum. However it also sug-
gests a decrease in long-term depression of the synapse 
and increases in long-term potentiation of cells, sug-
gesting an increase in synaptic plasticity and therefore 
strength in the cerebellum.
Genes known to be involved in the familial early-
onset form of AD, APP, PSEN1, and PSEN2, dis-
played varying levels of expression in the brain, with 
APP exhibiting high levels of expression, with PSEN1 
and PSEN2 genes showing a lower level of expression 
(Fig.  1). Expression levels of APP and PSEN1 were 
observed to significantly lower in the cerebellum, 
whereas PSEN2 was higher.
The RNA-sequencing data for genes associated with 
the late-onset form of AD suggested considerable varia-
tion for the average level of gene expression (Fig. 1). Of 
particular note is that genes involved in immunity path-
ways were found to show very low levels of gene expres-
sion on average across all brain regions (RPKM ≤ 1), 
whilst those involved in cholesterol metabolism and 
endocytosis displayed moderate (RPKM > 15) to high 
gene (RPKM > 100) expression levels.
Nine of the late-onset form AD-associated genes dis-
played no significant changes in expression level between 
regions of the brain (APOE, SORL1, TREM2, ABCA7, 
ZCWPW1, HLA-DRB5, MS4A64, CASS4, and TREML2). 
Three genes displayed a significantly higher in expression 
in the cerebellum compared to all other cortex regions 
(CELF1, CD2AP and EPHA1), whilst six genes displayed 
a significantly lower expression in the cerebellum (CLU, 
MEF2C, BIN1, FERMT2, SLC24A4 and INPP5D). Finally 
four genes displayed no significant change in expression 
between the regions of the brain except in one compari-
son with the cerebellum (Table 2).
The data generated here has a high level of concord-
ance with data from GTEx version 6 (v6). The compari-
son of medium RPKM values between our data and that 
obtained for brain regions available in GTEx are highly 
correlated for frontal (Pearson r = 0.974 P < 0.001) and 
cerebellum regions (Pearson r = 0.966 P < 0.001). Data 
from GTEx also supports the data for direction change 
in expression levels between the frontal and cerebellum 
regions, with 17 genes showing distinguishable levels of 
RPKM change between the regions, 14 of them (82.4%) 
are concordant with the data generated here. Discordant 
genes were PTK2B, SORL1 and BIN1, showing the oppo-
site direction of change in RPKM in the data provided 
here with that of GTEx v6.
Discussion
The number of genes that exhibited expression differ-
ences between the different cortex regions of the brain 
were not above what was expected by chance, decreas-
ing the credibility of those observations being true-pos-
itive findings. The key findings were the unique profile 
of the cerebellum gene expression, and the commonal-
ity of the genes differentially expressed between each of 
the four cortex comparisons. This echoes the findings by 
previous studies carried out using microarray technol-
ogy [11–13]. These studies compared gene expression in 
the cerebellum to various other regions of the brain, and 
observed that while cortex regions had little variation of 
gene expression between them, when compared to the 
cerebellum over 1000 genes were found to be differen-
tially expressed. The increased number of differentially 
expressed genes observed here, may reflect the greater 
accuracy and sensitivity of sequencing data over that of 
Table 1 Numbers of significantly differentially expressed genes identified by ‘DESeq2’ between brain regions (Benjamini-
Hochberg adjusted significance level of < 0.05; top right corner), and  numbers of  significantly differentially expressed 
genes filtered by fold-change of greater than doubled or halved expression changes (bottom left corner)
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microarray data. Tentatively, the most interesting obser-
vation was from the pathway analysis which suggests 
that the cerebellum has increased synaptic plasticity and 
strength, with the gene expression changes suggesting an 
increase in long-term potentiation of the cells, despite 
a decrease in the development and quantity of neurons. 
Synapse plasticity and therefore strength of cell–cell sig-
nalling is thought to underlie learning and memory [14].
A previous investigation of gene expression changes 
related to aging across different regions of the brain 
identified that whereas several regions of the brain dis-
played similar age-related gene expression changes to 
the frontal cortex, the cerebellum displays little correla-
tion with these regions [15]. Their analysis suggests that 
the cerebellum shows fewer gene expression changes in 
relation to aging compared to other parts of the brain, 
which may account for the large number and common-
ality of gene differentially expressed between the cer-
ebellum and cortex regions presented here. One of the 
suggestions by Fraser et al. [15] was that the cerebellum 
could be aging at a slower rate than other regions of the 
brain, and these differentially expressed genes might 
represent those associated with aging.
The cerebellum has long thought to be relatively 
preserved in AD [16, 17], and PET studies have uti-
lized the cerebellum as a pseudo-control investigat-
ing neuro-inflammation due to the lack of difference 
shown for TSPO density between patients with AD 
and controls [18, 19]. This might possibly suggest that 
the cerebellum has some protective measures against 
the onset of aging and/or AD pathology. This however 
requires further exploration and could be the basis of 
gaining insight into the preservation of neurons in the 
brain and therefore therapeutic intervention.
This was further supported by the observation of 
genes that are purportedly associated with AD (famil-
ial and sporadic) via association studies display higher 
or lower expression levels in the cerebellum compared 
to cortex regions.
Fig. 1 Graphic showing the mapping of key associated Alzheimer’s disease genes mapped on to pathways and their relative gene expression 
determined by RNA‑sequencing RPKMs [8]. Genes involved in Cholesterol Metabolism and Endocytosis pathways are highly expressed in the 
brain, whilst genes involved in Immunity pathways show little expression in the brain (Figure Adapted from Medway and Morgan 2014)
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It was found that some genes known to be involved 
in the familial and in the late-onset form of AD, were 
in fact expressed at low levels in the brain with some 
expressed at RPKM values below the cut-off that would 
indicate the levels could not be discriminated against 
background noise [9]. This was supported with expres-
sion data from GTEx v6. In particular genes known 
to be associated with late-onset AD, involved in the 
immunity pathway, now a leading focus for therapeu-
tic investigation for the disease, are expressed at very 
low levels in the brain. Data from GTEx suggests these 
genes involved in the immunity pathway are highly 
expressed in tissues such as whole blood, the lung and 
spleen.
Limitations
This pilot study lacks the power to discern real data on 
the variability between individuals. However it pro-
vides valuable data for gene expression across human 
brains regions for future reference. Ideally further RNA-
sequencing of more specific brain regions on control and 
Alzheimer’s disease samples would add greater power to 
the study.
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